46
Participants
Start Date
January 1, 2024
Primary Completion Date
September 30, 2025
Study Completion Date
December 31, 2025
Empagliflozin 10 mg
The primary objective was to evaluate the efficacy of early treatment with empagliflozin in reducing GV, as measured by the change in MAGE from baseline to Week 12, compared to metformin.
Metformin
The primary objective was to evaluate the efficacy of early treatment with empagliflozin in reducing GV, as measured by the change in MAGE from baseline to Week 12, compared to metformin.
RECRUITING
SNUBH, Seongnam
Seoul National University Bundang Hospital
OTHER